Corvus Pharmaceuticals to Reschedule R&D Day Due to Severe Winter Storm in the New York Tri-State Area

BURLINGAME, Calif., March 13, 2017 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, announced that the company will postpone its R&D Day scheduled for March 14, 2017 due to an anticipated severe winter snowstorm forecasted to hit the New York tri-state area and its impact on the travel schedule and participation of its principal presenters.

The company plans to reschedule the event within the first half of 2017 and will provide details of the rescheduled event as soon as that date is determined.

The company anticipates providing additional updates on its lead CPI-444 program as planned at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2017, which is taking place April 1-5 in Washington, D.C.

About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T-cells. Corvus’ lead product, CPI-444, is a checkpoint inhibitor that is designed to disable a tumor’s ability to subvert attack by the immune system by inhibiting adenosine in the tumor microenvironment. CPI-444 is a small molecule that is taken orally. CPI-444 is currently being evaluated in a multicenter Phase 1/1b clinical trial in patients with various solid tumors. This successive expansion cohort trial is examining the activity of CPI-444 both as a single agent and in combination with Genentech’s Tecentriq® (atezolizumab), an anti-PD-L1 antibody. Corvus is conducting the trial with Genentech, a member of the Roche Group, under a clinical trial collaboration the two companies entered into in October 2015. For more information, visit:

Tecentriq® is a registered trademark of Genentech.

CONTACT: Corvus Contact: 
Jason Coloma
SVP, Chief Business Officer
Corvus Pharmaceuticals, Inc. 

Media Contact
Julie Normart
Pure Communications